Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BA-1049
- Development stage
- Phase 1
- Lead developer
- Neurelis
- Modality
- Targeted Protein Degraders (TPDs) → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules, Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral, Intravenous (for Active Metabolite)
01
Overview
BA-1049 (also known as NRL-1049) is a selective small molecule inhibitor of Rho kinase 2 (ROCK2), developed for the treatment of cerebral cavernous malformations (CCM), also referred to as cavernous angioma. It is designed to reduce the accumulation of new lesions and alleviate neurological symptoms associated with CCMs by inhibiting ROCK2, which is implicated in vascular permeability and neuroinflammation. Preclinical studies have shown that BA-1049 reduces lesion volume and hemorrhagic transformation in mouse models of CCM, preserves blood-brain barrier integrity, and suppresses seizures. The drug has demonstrated an 86-fold selectivity for ROCK2 over ROCK1, making it highly targeted for central nervous system disorders. In addition to CCMs, preclinical data suggest potential utility in other neurological diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, spinal muscular atrophy (SMA), stroke, traumatic brain injury, optic nerve injury, peripheral nerve injuries, vasospasm after subarachnoid hemorrhage, hereditary hemorrhagic telangiectasia and Behcet's Disease[1][4][5][6][7][8][9].
- Other names
- NRL-1049NRL1049NRL 1049
02
Targets
ROCK2 (Rho-associated coiled-coil containing protein kinase 2)
Beyond the preview
Go deeper on BA-1049.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BA-1049.